Why Is This Cannabis Stock Up 62%?

OrganiGram Holdings Inc (TSXV:OGI) isn’t as popular as Green Organic Dutchman Holdings Ltd (TSX:TGOD) or Hexo Corp (TSX:HEXO), but it has a similar valuation. Is this a hidden gem or purely hype?

| More on:
Business man on stock market financial trade indicator background.

Image source: Getty Images

Despite having a share price of just $0.23 in 2015, OrganiGram Holdings Inc (TSXV:OGI) stock has quickly risen to a market cap of more than $1.3 billion. Since the start of 2019, shares are up another 62%.

Now with a valuation that rivals other notable pot stocks like Green Organic Dutchman Holdings Ltd (TSX:TGOD) and Hexo Corp (TSX:HEXO), why do shares seem to consistently move higher by large jumps every month? Is the latest 62% rise due to improving fundamentals or pure hype?

The optimism is warranted

As Fool contributor Keith Speights wrote in September, “OrganiGram hasn’t generated as much buzz as bigger Canadian marijuana stocks. But that might not be a bad thing.”

Since that article, shares have popped more than 100%. It seems that OrganiGram is finally getting the hype that nearly every other cannabis-related stock has received.

As with its competitors, OrganiGram is promoting its strong growth opportunities across Canada, as well as its leading cost position. Those are advantages that are found in every investor presentation across the entire industry. OrganiGram seems to be able to back the claims, however.

As a cannabis producer, OrganiGram is focused on ramping and expanding its three-level, indoor growing facility located in New Brunswick. By the end of 2019, production should hit 113,000 kilograms on an annualized basis, up from 36,000 kilograms at the start of the year. Green Organic Dutchman, by comparison, will only bring 14,000 kilograms of cannabis online this year.

OrganiGram is also one of only three companies with licensing agreements in all ten provinces. Management has been putting the pieces into place to capitalize on international growth opportunities as well.

In total, OrganiGram looks like an ideal way to capitalize on the cannabis boom. But what about the valuation?

Now it gets interesting

With less name recognition, it’s reasonable to be wary of OrganiGram’s $1.3 billion valuation, especially as better-known peers like Green Organic Dutchman and Hexo trade in a similar range. Looking at the fundamentals, however, OrganiGram is a relative bargain.

First, the company has enough cash on hand to fund its expansion plans this year, so dilution won’t be as necessary. Second, shares are simply a steal versus the rest of the cannabis industry.

Based on 2019 consensus estimates, the average cannabis stock trades at 226x EBITDA. OrganiGram stock trades at just 22x this year’s EBITDA.

Looking further ahead, the steep valuation gap remains. The average peer now trades at 53x 2020 EBITDA while OrganiGram is valued at just 14x EBITDA.

With a skilled management team, solid balance sheet, and reasonable growth targets, it’s tough to justify such a discounted valuation.

Your best bet?

If the cannabis market continues to take off, OrganiGram stock looks like a steal compared to competitors like Green Organic Dutchman and Hexo. Even if industry hype recedes, OrganiGram’s valuation has less room to contract.

Today, OrganiGram appears like a great way to play the cannabis market, even after its recent 62% run.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »